Cargando…

PSA mass as a marker of prostate cancer progression after radical prostatectomy

BACKGROUND: Obese patients with prostate cancer may have lower preoperative PSA concentration due to hemodilution. Lower PSA concentration may falsely affect assessing the risk of progression after radical prostatectomy (RP). The aim of this study was to determine preoperative PSA mass as the absolu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bryniarski, Piotr, Paradysz, Andrzej, Fryczkowski, Mieczysław
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2011
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524695/ https://www.ncbi.nlm.nih.gov/pubmed/21278686 http://dx.doi.org/10.12659/MSM.881395

Ejemplares similares

The impact of adjuvant therapy in patients with biochemical recurrence on prostate cancer progression and mortality five years after radical prostatectomy
por: Fryczkowski, Mieczysław, et al.
Publicado: (2011)

Prognostic value of radical cystoprostatectomy in men with bladder cancer infiltrating prostate versus co-existing prostate cancer: a research study
por: Bryniarski, Piotr, et al.
Publicado: (2010)

Role of preoperative patient education among prostate cancer patients treated by radical prostatectomy
por: Jurys, Tomasz, et al.
Publicado: (2022)

Testicular volume and fertility potential in men operated due to varicocele and testicular hypotrophy in adolescence
por: Bryniarski, Piotr, et al.
Publicado: (2013)

HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy
por: Zabalza, Cristina Villares, et al.
Publicado: (2015)

What is the possible role of PSA doubling time (PSADT) and PSA velocity (PSAV) in the decision-making process to initiate salvage radiotherapy following radical prostatectomy in patients with prostate cancer?
por: Milecki, Piotr, et al.
Publicado: (2011)

Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival
por: Doherty, A P, et al.
Publicado: (2000)

Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens
por: de Lima, Nelson Gianni, et al.
Publicado: (2013)

Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer
por: Fryczkowski, M., et al.
Publicado: (2018)

Elevated periprostatic venous testosterone correlates with prostate cancer progression after radical prostatectomy
por: Alyamani, Mohammad, et al.
Publicado: (2023)

The natural history of a delayed detectable PSA after radical prostatectomy
por: Szymaniak, Julie A., et al.
Publicado: (2023)

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer
por: Adamkiewicz, Mateusz, et al.
Publicado: (2021)

Occurrence of neutrophil dysplasia in the course of severe nephrotic syndrome in a 12-year-old boy on immunosuppressive therapy: Questions
por: Hyla-Klekot, Lidia, et al.
Publicado: (2016)

Occurrence of neutrophil dysplasia in the course of severe nephrotic syndrome in a 12-year-old boy on immunosuppressive therapy: Answers
por: Hyla-Klekot, Lidia, et al.
Publicado: (2016)

Heterophilic Antibodies Resulting in False Positive Elevation of PSA After Radical Prostatectomy
por: Asha, Wafa, et al.
Publicado: (2023)

Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL
por: Hinev, Alexander I., et al.
Publicado: (2012)

Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy()
por: Minner, Sarah, et al.
Publicado: (2019)

Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy
por: Cheng, Yung-Ting, et al.
Publicado: (2020)

Clinicopathological characteristics of localized prostate cancer in younger men aged ≤ 50 years treated with radical prostatectomy in the PSA era: A systematic review and meta‐analysis
por: Zheng, Yu, et al.
Publicado: (2020)

Ten-year treatment outcomes including blood cell count disturbances in patients with simple renal cysts
por: Bryniarski, Piotr, et al.
Publicado: (2013)

Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy
por: Ibeawuchi, Chinyere, et al.
Publicado: (2015)

Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience
por: Quero, Laurent, et al.
Publicado: (2008)

Comparison of Pathological and Biochemical Outcomes after Radical Prostatectomy in Korean Patients with Serum PSA Ranges
por: Lee, Hye Won, et al.
Publicado: (2015)

Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients
por: Kim, Jung Kwon, et al.
Publicado: (2019)

Percutaneous Nephrolithotomy with Amplatz and Alken Dilators: An Eight-Year Single Tertiary Care Centre Experience
por: Bryniarski, Piotr, et al.
Publicado: (2016)

Lack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical Prostatectomy
por: Maeda, Yoko, et al.
Publicado: (2016)

Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy
por: Ahn, Hyun Kyu, et al.
Publicado: (2020)

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy
por: Kang, Yong Jin, et al.
Publicado: (2017)

Evaluating PSA Density as a Predictor of Biochemical Failure after Radical Prostatectomy: Results of a Prospective Study after a Median Follow-Up of 36 Months
por: Sfoungaristos, Stavros, et al.
Publicado: (2013)

Significance of Time Until PSA Recurrence After Radical Prostatectomy Without Neo- or Adjuvant Treatment to Clinical Progression and Cancer-Related Death in High-Risk Prostate Cancer Patients
por: Venclovas, Zilvinas, et al.
Publicado: (2019)

Contemporary update of cancer control after radical prostatectomy in the UK
por: Winkler, M H, et al.
Publicado: (2004)

The Role of (11)C-Choline-PET/CT-Guided Secondary Lymphadenectomy in Patients with PSA Failure after Radical Prostatectomy: Lessons Learned from Eight Cases
por: Martini, Thomas, et al.
Publicado: (2012)

Sacrocolpopexy with Polypropylene Tape as Valuable Surgical Modification during Cystectomy with Orthotopic Ileal Bladder: Functional Results
por: Życzkowski, Marcin, et al.
Publicado: (2015)

Reduction in PSA messenger-RNA expression and clinical recurrence in patients with prostatic cancer undergoing neoadjuvant therapy before radical prostatectomy
por: Grasso, Marco, et al.
Publicado: (2004)

[−2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report
por: De Luca, S., et al.
Publicado: (2016)

Robotic Prostatectomy Has a Superior Outcome in Larger Prostates and PSA Density Is a Strong Predictor of Biochemical Recurrence
por: Bishara, S., et al.
Publicado: (2014)

Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy
por: Xu, Fan, et al.
Publicado: (2016)

Functional recovery after radical prostatectomy for prostate cancer
por: Ko, Young Hwii
Publicado: (2018)

Novel hematological biomarkers predict survival in renal cell carcinoma patients treated with nephrectomy
por: Rajwa, Paweł, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fpnlglhbu6skp5subfneb3jec8